Adicet Bio Company Insiders
| ACET Stock | USD 2.10 0.10 5.00% |
Adicet Bio's insiders are aggressively buying. The analysis of insiders' sentiment of trading Adicet Bio stock suggests that vertually all insiders are extremely bullish at this time. Adicet Bio employs about 143 people. The company is managed by 32 executives with a total tenure of roughly 255 years, averaging almost 7.0 years of service per executive, having 4.47 employees per reported executive.
| Salvatore Guccione CEO CEO and President and Director |
| Albert Eilender Chairman Chairman of the Board |
Adicet Bio's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-01-25 | Orbimed Advisors Llc | Acquired 3125000 @ 2.4 | View | ||
| 2023-10-02 | Chen Schor | Acquired 5500 @ 1.33 | View | ||
| 2023-09-28 | Chen Schor | Acquired 5500 @ 1.42 | View | ||
| 2023-06-30 | Steve Dubin | Acquired 5000 @ 2.4 | View | ||
| 2023-06-27 | Carl L Gordon | Acquired 875000 @ 2.09 | View |
Monitoring Adicet Bio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Adicet |
Adicet Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.308) % which means that it has lost $0.308 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6169) %, meaning that it created substantial loss on money invested by shareholders. Adicet Bio's management efficiency ratios could be used to measure how well Adicet Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.65 in 2024. Return On Capital Employed is likely to gain to -0.67 in 2024. Liabilities And Stockholders Equity is likely to gain to about 214.3 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 18.3 M in 2024.Common Stock Shares Outstanding is likely to drop to about 28.5 M in 2024
Adicet Bio Workforce Comparison
Adicet Bio is rated below average in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 2,737. Adicet Bio holds roughly 143 in number of employees claiming about 5% of equities under Health Care industry.
Adicet Bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adicet Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adicet Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Adicet Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Schor Chen over six months ago Acquisition by Schor Chen of 240000 shares of Adicet Bio subject to Rule 16b-3 | ||
Schor Chen over six months ago Sale by Schor Chen of 5500 shares of Adicet Bio | ||
Silverstein Jonathan over a year ago Conversion by Silverstein Jonathan of 2425482 shares of Adicet Bio | ||
Schor Chen over a year ago Bona fide gift to Schor Chen of 26712 shares of Adicet Bio subject to Section 16 |
Adicet Bio Notable Stakeholders
An Adicet Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Adicet Bio often face trade-offs trying to please all of them. Adicet Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Adicet Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Salvatore Guccione | CEO and President and Director | Profile | |
| Albert Eilender | Chairman of the Board | Profile | |
| Terry Kippley | Senior Vice President - Agricultural Protection Products | Profile | |
| Satish Srinivasan | President and COO of Rising Pharmaceuticals | Profile | |
| Carlos Restrepo | Senior Vice President - Performance Chemicals | Profile | |
| Vimal Kavuru | President of Rising | Profile | |
| Nicholas Shackley | Senior Vice President - Pharmaceutical Ingredients | Profile | |
| Charles Alaimo | Senior Vice President - Human Resources | Profile | |
| Raymond Bartone | Senior Vice President - Nutritionals | Profile | |
| Edward Borkowski | CFO | Profile | |
| Rebecca Roof | Interim CFO | Profile | |
| Douglas Roth | CFO, Principal Accounting Officer, Chief Admin. Officer, Sr. VP, Treasurer and Assistant Secretary | Profile | |
| Walter Kaczmarek | COO | Profile | |
| Frank DeBenedittis | Sr. VP of Corporate Bus. Devel. and International Sr. VP of Active Pharmaceutical Ingredients | Profile | |
| Steven Rogers | Sr. VP, General Counsel and Corporate Secretary | Profile | |
| Hans Noetzli | Lead Independent Director | Profile | |
| Natasha Giordano | Director | Profile | |
| Alan Levin | Independent Director | Profile | |
| Daniel Yarosh | Director | Profile | |
| William Britton | Independent Director | Profile | |
| Richard Randall | Independent Director | Profile | |
| William Kennally | Director | Profile | |
| Francesco MD | Chief VP | Profile | |
| BA CPA | Pres CEO | Profile | |
| Jody Burfening | IR Contact Officer | Profile | |
| Blake Aftab | Senior Officer | Profile | |
| Amy Locke | Head Resources | Profile | |
| Frances Scally | Chief Accounting Officer | Profile | |
| Donald Healey | Chief Officer | Profile | |
| Brian Harvey | Chief Officer | Profile | |
| Fran Scally | Chief Accounting Officer | Profile | |
| Aya Jakobovits | Founder Director | Profile |
About Adicet Bio Management Performance
The success or failure of an entity such as Adicet Bio often depends on how effective the management is. Adicet Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Adicet management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Adicet management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.69) | (0.65) | |
| Return On Capital Employed | (0.71) | (0.67) | |
| Return On Assets | (0.69) | (0.65) | |
| Return On Equity | (0.84) | (0.80) |
The data published in Adicet Bio's official financial statements usually reflect Adicet Bio's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Adicet Bio. For example, before you start analyzing numbers published by Adicet accountants, it's critical to develop an understanding of what Adicet Bio's liquidity, profitability, and earnings quality are in the context of the Health Care Providers & Services space in which it operates.
Please note, the presentation of Adicet Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Adicet Bio's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Adicet Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Adicet Bio. Please utilize our Beneish M Score to check the likelihood of Adicet Bio's management manipulating its earnings.
Adicet Bio Workforce Analysis
Traditionally, organizations such as Adicet Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Adicet Bio within its industry.Adicet Bio Manpower Efficiency
Return on Adicet Bio Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 997.6K | |
| Net Loss Per Executive | 4.5M | |
| Working Capital Per Employee | 999.9K | |
| Working Capital Per Executive | 4.5M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adicet Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For more information on how to buy Adicet Stock please use our How to Invest in Adicet Bio guide.Note that the Adicet Bio information on this page should be used as a complementary analysis to other Adicet Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Adicet Stock analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |
Is Adicet Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adicet Bio. If investors know Adicet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adicet Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.31) | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.62) |
The market value of Adicet Bio is measured differently than its book value, which is the value of Adicet that is recorded on the company's balance sheet. Investors also form their own opinion of Adicet Bio's value that differs from its market value or its book value, called intrinsic value, which is Adicet Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adicet Bio's market value can be influenced by many factors that don't directly affect Adicet Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adicet Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Adicet Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adicet Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.